Denali Therapeutics Inc.
Clinical trials sponsored by Denali Therapeutics Inc., explained in plain language.
A biopharmaceutical company developing therapies for neurodegenerative diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for rare dementia: experimental drug DNL593 enters human trials Results expected Dec 2026 (estimated)
- New Alzheimer's drug enters early human testing Results expected Feb 2027 (estimated)
- Promising new drug targets genetic Parkinson's in early trial Results expected Mar 2027 (estimated)
- New hope for hunter syndrome: Long-Term drug trial launches Results expected Jun 2027 (estimated) May already have reported ↗
-
Can a new drug tame Alzheimer's? early trial aims to find out
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called DNL921 to see if it is safe and tolerable for people. It will involve healthy volunteers and people with Alzheimer's disease, who will receive either the drug or a placebo. The main goal is to gather safety data and un…
Phase 1 • Sponsor: Denali Therapeutics Inc. • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug DNL952 enters human testing for pompe disease
Disease control Recruiting nowThis early-stage trial is testing a new drug called DNL952 in 32 adults with late-onset Pompe disease. The main goal is to check if the drug is safe and how the body processes it. Participants will receive the drug through an IV infusion at different doses.
Phase 1 • Sponsor: Denali Therapeutics Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New Alzheimer's drug enters early human testing
Disease control Recruiting nowThis study is testing an experimental drug called DNL628 in people with early-stage Alzheimer's disease. The main goal is to see if the drug is safe and how the body processes it. About 68 participants will receive either DNL628 or a placebo. This is an early-phase trial, so it f…
Phase 1 • Sponsor: Denali Therapeutics Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC